Fariha Karim

Ms. Fariha Karim

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YSYasmin Kaur Sandhu
Yasmin Kaur Sandhu
HBHarman Singh Bath
Harman Singh Bath
JSJasmine Shergill
Jasmine Shergill
CLChristopher Liang
Christopher Liang
ASAmina U Syed
Amina U Syed
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
The diagnostic value of imaging Aβ plaques in Alzheimer’s disease (AD) has accelerated the development of fluorine-18 labeled radiotracers with a longer half-life for easier translation to clinical use. We have developed [18F]flotaza, which shows high binding to Aβ plaques in postmortem human AD brain slices with low white matter binding. We report the binding of [18F]flotaza in postmortem AD hippocampus compared to cognitively normal (CN) brains and the evaluation of [18F]flotaza in transgenic 5xFAD mice expressing Aβ plaques. [18F]Flotaza binding was assessed in well-characterized human postmortem brain tissue sections consisting of HP CA1-subiculum (HP CA1-SUB) regions in AD (n = 28; 13 male and 15 female) and CN subjects (n = 32; 16 male and 16 female). Adjacent slices were immunostained with anti-Aβ and analyzed using QuPath. In vitro and in vivo [18F]flotaza PET/CT studies were carried out in 5xFAD mice. Post-mortem human brain slices from all AD subjects were positively IHC stained with anti-Aβ. High [18F]flotaza binding was measured in the HP CA1-SUB grey matter (GM) regions compared to white matter (WM) of AD subjects with GM/WM > 100 in some subjects. The majority of CN subjects had no decipherable binding. Male AD exhibited greater WM than AD females (AD WM♂/WM♀ > 5; p < 0.001) but no difference amongst CN WM. In vitro studies in 5xFAD mice brain slices exhibited high binding [18F]flotaza ratios (>50 versus cerebellum) in the cortex, HP, and thalamus. In vivo, PET [18F]flotaza exhibited binding to Aβ plaques in 5xFAD mice with SUVR~1.4. [18F]Flotaza is a new Aβ plaque PET imaging agent that exhibited high binding to Aβ plaques in postmortem human AD. Along with the promising results in 5xFAD mice, the translation of [18F]flotaza to human PET studies may be worthwhile.

28 March 2025 in Brain Research
Verified
Journal Article
Open access
FKFariha Karim
Fariha Karim
ANAllyson Ngo
Allyson Ngo
TDTram B. Danh
Tram B. Danh
BDBrooke Delaney
Brooke Delaney
CLChristopher Liang
Christopher Liang
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
Nicotinic acetylcholinergic receptors (nAChRs), including the α4β2* subtype are involved in cognition, learning and memory and may be adversely affected in Alzheimer's disease (AD). In our efforts to consider translational use of [18F]nifene PET in AD, we report quantitative autoradiographic evaluation of α4β2* nAChRs using hippocampus-subiculum (HP-SUB) from cognitively normal (CN) and AD subjects. Brain slices were incubated in [18F]nifene for α4β2* nAChRs and adjacent sections were tested with [18F]flotaza for Aβ plaques and [125I]IPPI for tau. Anti-Aβ and anti-tau immunostaining were carried out on adjacent slices. Regions of interest were drawn and binding of [18F]nifene, [18F]flotaza and [125I]IPPI were quantified.All CN subjects exhibited significant [18F]nifene binding in the HP-SUB regions. Average [18F]nifene ratios of SUB to HP was 1.9, suggesting higher α4β2* nAChRs in the SUB versus HP regions. [18F]nifene binding did not change with aging in the female subjects, while the male subjects exhibited a weak positive correlation. There was a significant decrease in the binding of [18F]nifene in AD subjects compared to CN. Braak stage comparisons showed a decrease of [18F]nifene in stages V and VI, while [18F]flotaza and [125I]IPPI increased significantly. A negative correlation was observed between [18F]nifene vs [18F]flotaza and [18F]nifene vs [125I]IPPI across Braak stages I-VI. These findings suggest that α4β2* nAChR availability was effectively measured by [18F]nifene in the HP-SUB and was adversely affected by the presence of Aβ plaques and tau.

21 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
CPCayz Paclibar
Cayz Paclibar
DSDeanna Marissa Schafer
Deanna Marissa Schafer
ABAgnes Biju
Agnes Biju
FKFariha Karim
Fariha Karim
SSStephanie A. Sison
Stephanie A. Sison
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
Dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), a phosphorylation kinase, is localized within the central nervous system and is linked to hyperphosphorylation of Tau. Imaging of DYRK1A may provide an earlier biomarker for Tauopathies, including Alzheimer’s disease (AD). We have used Chimera-Autodock to evaluate potential molecules for binding to the binding site of DYRK1A. Five molecules, 10-bromo-2-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (4E3), 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (KuFal184), harmine, 6-(fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine (MK-6240), and 6-iodo-3-(1H-pyrrolo[2,3-c]pyridine-1-yl)isoquinoline (IPPI), were found to have binding energies of −10.4, −10.1, −9.0, −9.1, and −9.4 kcal/mole, respectively. Two molecules, 4E3 and KuFal184, were selective for DYRK1A, while harmine also had a monoamine oxidase A affinity, and MK-6240 and IPPI had affinity for Tau. Tau present in the brain slices of AD subject were labeled with [125I]IPPI. KuFal184 had no effect on the binding of [125I]IPPI, suggesting the absence of binding overlap of the two molecules. MK-6240, a known Tau agent was, however, able to compete with [125I]IPPI. The binding energies of harmine, MK-6240, and IPPI for the DYRK1A site suggest affinities of approximately 80–100 nM, which is insufficient to serve as an imaging agent. The higher affinity of KuFal184 (6 nM for DYRK1A) suggested that [125I]KuFal184 may be a potential imaging agent. Electrophilic radioiodination was used to synthesize [125I]KuFal184 in modest yields (25%) and high radiochemical purity (>95%). Preliminary binding studies with [125I]KuFal184 in AD brain slices showed some selectivity for cortical grey matter regions containing Tau.

6 July 2025 in Synapse
Verified
Journal Article
Open access
FKFariha Karim
Fariha Karim
BDBrooke A. Delaney
Brooke A. Delaney
RMRommani Mondal
Rommani Mondal
CLChristopher Liang
Christopher Liang
GSGeidy E. Serrano
Geidy E. Serrano
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
Alzheimer's disease (AD) is characterized by the accumulation of tau tangles that aggregate into neurofibrillary tangles (NFT). This study aims to assess binding of [125I]IPPI, a recently reported imaging probe for pathological, aggregated tau in AD human hippocampus (HP) postmortem brain slices, and measure effects of drugs known to bind to tau, monoamine oxidase A (MAO‐A), and dual specificity tyrosine‐phosphorylation regulated kinase 1A (DYRK1A). Quantitative [125I]IPPI binding was compared between AD (n = 29; 13 male and 16 female) and cognitively normal (CN) (n = 32; 16 male and 16 female) subjects. Significantly, there was more [125I]IPPI binding in AD gray matter (GM), which positively correlated with the percent of anti‐tau immunostaining. GM/white matter (WM) ratios in AD were higher compared to CN subjects. Female AD (avg. GM/WM = 2.42) exhibited greater [125I]IPPI binding compared to males (avg. GM/WM = 1.91). Binding of [125I]IPPI increased with Braak neurofibrillary stages of the subjects, and the effects of aging were mixed, with females showing a downward trend. A positive correlation between [125I]IPPI binding to tau and [18F]flotaza binding to amyloid beta (Aβ) suggests potential pathophysiological associations between the two AD biomarkers. MK‐6240 (aggregated tau‐selective) and harmine (MAO‐A, DYRK1A, and tau nonselective) inhibited [125I]IPPI binding by 88% and 69%, respectively. No effect on [125I]IPPI binding was observed by selective DYRK1A (KuFal194) and MAO‐A (clorgyline) inhibitors. Affinity of harmine for tau binding sites was quantified by inhibitor concentration (IC50) = 135 ± 29 nM. This study demonstrates promise of radiolabeled IPPI as a viable and selective tau radiotracer to assist in the diagnostic imaging of AD in humans.

20 March 2025 in Receptors
Verified
Journal Article
Open access
PDF file
ANAllyson Ngo
Allyson Ngo
FKFariha Karim
Fariha Karim
OKOshini V. Keerthisinghe
Oshini V. Keerthisinghe
TDTram B. Danh
Tram B. Danh
CLChristopher Liang
Christopher Liang
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
Background/Objectives: Alzheimer’s disease (AD) severely hinders cognitive function in the hippocampus (HP) and subiculum (SUB), impacting the expression of nicotinic acetylcholine receptors (nAChRs) such as the α7-subtype. To investigate α7 nAChRs as a potential PET imaging biomarker, we report the quantitative binding of [125I]α-Bungarotoxin ([125I]α-Bgtx) for binding to postmortem human AD (n = 29; 13 males, 16 females) HP compared to cognitively normal (CN) (n = 28; 13 male, 15 female) HP. Methods: For comparisons with common AD biomarkers, adjacent slices were anti-Aβ and anti-Tau immunostained for analysis using QuPath. Results: The [125I]α-Bgtx average SUB/HP ratio was 0.5 among the CN subjects, suggesting higher [125I]α-Bgtx binding in the HP gray matter regions. The AD subjects showed overall less binding than the CN subjects, with no statistical significance. A positive correlation was found in the [125I]α-Bgtx binding in the AD subjects as the age increased. The Braak stage comparisons of [125I]α-Bgtx were made with [18F]flotaza binding to Aβ plaques and [125I]IPPI binding to Tau. A positive correlation was found between [125I]α-Bgtx and [18F]flotaza and there was a negative correlation between [125I]α-Bgtx and [125I]IPPI, implicating intricate relationships between the different AD biomarkers. Conclusions: [125I]α-Bgtx shows complimentary potential as a α7 nAChR imaging agent but needs more preclinical assessments to confirm effectiveness for translational PET studies using α7 nAChR radioligands.

16 April 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
NGNoresa L. Gonzaga
Noresa L. Gonzaga
FKFariha Karim
Fariha Karim
CLChristopher Liang
Christopher Liang
Jogeshwar MukherjeeJogeshwar Mukherjee
Jogeshwar Mukherjee
Serotonin 5HT1A receptors may be affected in neurodegeneration, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Using the selective 5HT1A receptor positron emission tomography (PET) imaging agent, [18F]mefway, autoradiographic studies from postmortem human brains of AD, PD, and cognitively normal (CN) subjects were carried out. Levels of [18F]mefway binding were compared with monoamine oxidase A (MAO-A) measured using [18F]FAZIN3 binding and dopamine D2/D3 receptors measured using [18F]fallypride binding in the same subjects. Autoradiograms of brain sections of the anterior cingulate and corpus callosum from CN, PD, and AD subjects (n = 6 in each group) were analyzed. Significant increased binding of [18F]mefway was found in the AD (+30%) and PD (+11%) brains compared to CN brains. This increase positively correlated to increased [18F]FAZIN3 binding, suggesting greater 5HT1A receptor availability when MAO-A levels are higher. Differences in [18F]fallypride binding in the three groups were not significant. Our results support the finding that the availability of 5HT1A receptors in AD and PD is elevated in the anterior cingulate cortex and is negatively correlated with MAO-A. This upregulation may potentially be a response to lower serotonin levels due to the increased levels of MAO-A activity in this brain region or other neuroinflammatory changes. Thus, 5HT1A receptors may be a potential target for diagnostic and therapeutic approaches for AD and PD.